Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed - Biologic Drug Details

Summary for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

Tradenames:	2
High Confidence Patents:	0
Applicants:	2
BLAs:	2
Suppliers: see list	3
Recent Clinical Trials:	See clinical trials for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

Recent Clinical Trials for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1

See all tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed clinical trials

Pharmacology for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Bordetella Pertussis Vaccine Inactivated Clostridium Tetani Vaccine Inactivated Corynebacterium Diphtheriae Vaccine
Chemical Structure	Diphtheria Toxoid Pertussis Vaccine Tetanus Toxoid Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Glaxosmithkline Biologicals	BOOSTRIX	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125106		2033-03-08	DrugPatentWatch analysis and company disclosures
Glaxosmithkline Biologicals	BOOSTRIX	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125106		2036-05-24	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2035-05-12	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2015-05-04	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2016-10-17	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2018-07-10	DrugPatentWatch analysis and company disclosures
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2018-10-15	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2036-12-20	Patent claims search
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2038-12-19	Patent claims search
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2038-07-09	Patent claims search
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2034-03-11	Patent claims search
Sanofi Pasteur Limited	ADACEL	tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed	Injection	125111		2034-02-28	Patent claims search

International Patents for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed

Country	Patent Number	Estimated Expiration
China	101133158
Spain	2432968
Poland	1851315
World Intellectual Property Organization (WIPO)	2016030455
Australia	2025202908
Canada	2741176
Serbia	59134

Market Dynamics and Financial Trajectory for the Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)

Last updated: February 15, 2026

What is the Current Market Size for Tdap Vaccines?

The global Tdap vaccine market was valued at approximately $4.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of roughly 6% from 2023 to 2030, reaching around $6.5 billion by 2030. The growth correlates with increased adult vaccination initiatives and healthcare policies emphasizing pertussis prevention.

Key drivers of market expansion include:

• Rising awareness regarding vaccine-preventable diseases.
• Implementation of adult immunization programs.
• Enhanced vaccination coverage in vulnerable populations, including pregnant women.
• Increasing demand in emerging markets with expanding healthcare infrastructure.

Major players such as Sanofi Pasteur, GlaxoSmithKline (GSK), and Merck & Co. dominate the market, holding combined shares exceeding 70%. Recent product launches and pipeline developments aim to address demand for more thermostable and immunogenic formulations.

How Have Market Trends Influenced Revenue and Investment?

Growth Factors

Regulatory Support: Governments and health authorities, especially in North America and Europe, have mandated adult pertussis vaccination, boosting demand. The CDC recommends Tdap for pregnant women and close contacts of infants, expanding the market scope.

Manufacturing Innovation: Technological advances facilitate production of adsorbed formulations with improved shelf life and reduced side effects. The most common formulation, adsorbed Tdap, maintains high stability and immunogenicity.

Pandemic Impact: COVID-19 shifted focus to adult boosters and routine vaccinations, temporarily disrupting supply chains but also highlighting the importance of adult immunization strategies.

Investment Trends

Vaccine companies have increased R&D to develop next-generation formulations, including:

• DNA-based Tdap vaccines.
• Longer-lasting immunogenic formulations.
• Combination vaccines targeting multiple pathogens.

These initiatives secure future revenue streams and market share. Funding from government agencies and nonprofit organizations supports vaccine research and distribution, particularly in low-income regions.

What Are the Key Market Drivers and Challenges?

Drivers

• Growing incidence of pertussis outbreaks, especially among adults.
• Public health campaigns promoting adult immunizations.
• Policy shifts advocating for booster doses in adolescents and adults.
• Development of combination vaccines simplifying immunization schedules.

Challenges

• Vaccine hesitancy impacting coverage rates.
• High manufacturing costs constraining price competitiveness.
• Limited market penetration in certain developing countries due to affordability and distribution issues.
• Variability in healthcare infrastructure and vaccination policies.

How Do Regulatory and Policy Factors Impact Market Trajectory?

Regulatory agencies such as the FDA and EMA require rigorous safety and efficacy data for vaccine approval. These bodies have approved multiple Tdap formulations, streamlining commercialization but also prolonging development timelines for new formulations.

Government policies influence market growth by:

• Subsidizing vaccination programs.
• Including Tdap in national immunization schedules.
• Mandating vaccination for healthcare workers and pregnant women.

Countries with strong immunization mandates see higher vaccine uptake, reinforcing market stability.

What Is the Financial Outlook for Manufacturers?

Manufacturers' revenue depends on several factors:

• Demand driven by adult immunization campaigns.
• Pipeline product approvals and launches.
• Pricing strategies aligned with healthcare systems' reimbursement policies.
• Competitive landscape, with patent expirations influencing generics and biosimilar entries.

Gross margins for established products like GSK's Adacel and Sanofi's Boostrix remain robust, supported by well-established manufacturing processes. Investment in pipeline candidates aims to extend market share and revenue.

Which Markets Present High Growth Potential?

Regions with high unmet needs and increasing health expenditure include:

• Asia-Pacific: projected CAGR of 8%, fueled by expanding healthcare infrastructure.
• Latin America: growing immunization programs and rising awareness.
• Middle East and Africa: emerging markets with increasing vaccine access and government support.

Market entry strategies involve local partnerships, technology transfer, and tiered pricing models to improve affordability.

How Are Future Developments Shaping Market Outlook?

Emerging innovations include:

• Thermostable formulations reducing cold chain dependencies.
• Novel adjuvants enhancing immunogenicity.
• Digital tracking for vaccination compliance.
• Combination vaccines integrating Tdap with other immunizations.

These developments aim to sustain growth, improve coverage, and address logistical challenges.

---

Key Takeaways

• The global Tdap vaccine market is valued at over $4 billion (2022) with a projected CAGR of 6%, driven by adult vaccination initiatives and public health policies.
• Leading companies maintain dominant market shares through established products and pipeline development.
• Growth is tempered by vaccine hesitancy, high manufacturing costs, and distribution challenges in low-income regions.
• Regulatory and policy environments significantly influence market trajectory, with mandates and immunization programs acting as growth catalysts.
• Innovative formulations and combination vaccines are expected to sustain market expansion and opening new geographic opportunities.

---

FAQs

Q1: What are the main formulations of Tdap vaccines?
Most marketed vaccines are adsorbed, containing tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis components. These are administered as injectable, combination, or standalone vaccines.

Q2: Which regions are experiencing the fastest growth for Tdap vaccines?
Asia-Pacific and Latin America show the highest CAGR owing to expanding healthcare systems, increased disease awareness, and growing immunization programs.

Q3: How do regulatory policies influence vaccine market growth?
Approval processes set standards for safety and efficacy, affecting product availability. Policies mandating adult vaccination increase demand and market stability.

Q4: What are the primary challenges facing Tdap vaccine manufacturers?
Public vaccine hesitancy, high production costs, limited distribution infrastructure in developing markets, and competition from biosimilars impact revenue.

Q5: What innovations are expected to shape the future of Tdap vaccines?
More thermostable formulations, longer-lasting immunogenicity, combination vaccines, and digital tracking systems aim to improve efficacy, coverage, and logistics.

---

References:

[1] MarketWatch, "Global Tdap Vaccine Market Size, Share & Trends Analysis Report" (2022).
[2] GlobalData, "Vaccine Market Outlook" (2023).
[3] CDC, "Updated Recommendations for Tdap Vaccination" (2022).